temozolomide has been researched along with Benign Supratentorial Neoplasms in 41 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Disulfiram, a generic alcohol aversion drug, has promising preclinical activity against glioblastoma (GBM)." | 9.22 | A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy. ( Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, CI, 2016) |
| "The purpose of phase 1 was to determine the maximum tolerated dose (MTD) of motexafin gadolinium (MGd) given concurrently with temozolomide (TMZ) and radiation therapy (RT) in patients with newly diagnosed supratentorial glioblastoma multiforme (GBM)." | 9.20 | Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513. ( Ashby, LS; Bovi, JA; Brachman, DG; Curran, WP; Dunbar, EM; Narayan, S; Pugh, SL; Robins, HI; Rockhill, JK; Thomas, TA; Won, M, 2015) |
| " Temozolomide (TMZ) is an alkylating agent that is the first-line chemotherapy for glioblastoma." | 9.17 | Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. ( Colman, H; Conrad, C; Gilbert, MR; Groves, M; Hsu, S; Kang, S; Levin, V; Liu, D; Liu, V; Puduvalli, V; Yuan, Y; Yung, WK; Yust-Katz, S, 2013) |
| "External beam radiation therapy (XRT) with concomitant temozolomide and 6 cycles of adjuvant temozolomide (5/28-day schedule) improves survival in patients with newly diagnosed glioblastoma compared with XRT alone." | 9.14 | A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. ( Chang, E; Colman, H; Conrad, C; de Groot, J; Giglio, P; Gilbert, MR; Gonzalez, J; Groves, MD; Hess, K; Hunter, K; Levin, V; Mahajan, A; Puduvalli, V; Woo, S; Yung, WK, 2010) |
| "This Phase II study was designed to determine the median survival time of adults with supratentorial glioblastoma treated with a combination of temozolomide (TMZ) and 13-cis-retinoic acid (cRA) given daily with conventional radiation therapy (XRT)." | 9.11 | A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. ( Butowski, N; Chang, SM; Lamborn, KR; Larson, DA; Malec, M; Page, M; Prados, MD; Rabbitt, J; Sneed, PK; Wara, WM, 2005) |
| "Twenty-one patients with recurrent or progressive glioblastoma were enrolled in a prospective phase II trial to determine the safety and efficacy of a 1-week on/1-week off regimen of temozolomide administered at 150 mg/m2 on days 1 to 7 and days 15 to 21 of 28-day treatment cycles." | 9.11 | One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. ( Bamberg, M; Dichgans, J; Küker, WM; Steinbach, JP; Weller, M; Wick, W, 2004) |
| "Temozolomide (TMZ) and 13-cis-retinoic acid (cRA) have shown activity in prior single-agent trials of recurrent malignant gliomas (MG)." | 9.10 | Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. ( Chang, S; Cloughesy, T; Fine, H; Fink, K; Greenberg, H; Hess, KR; Jaeckle, KA; Kuhn, J; Mehta, M; Nicholas, MK; Pollack, IF; Prados, M; Schiff, D; Yung, WK, 2003) |
| "Combined temozolomide (TMZ) and radiation therapy (RT) is often used as initial treatment for anaplastic glioma." | 7.79 | Combined temozolomide and radiation as an initial treatment for anaplastic glioma. ( Chong, DQ; Chua, ET; Lim, KH; Ng, WH; See, SJ; Tan, SH; Tham, CK; Thomas, J, 2013) |
| "Study the feasibility and effectiveness of a treatment associated surgery, intraoperative chemotherapy (carmustine wafers), and concomitant radiochemotherapy (temozolomide) for the management of newly diagnosed, high-grade gliomas." | 7.79 | Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. ( Colin, P; Debreuve, A; Duntze, J; Eap, C; Emery, E; Guillamo, JS; Jovenin, N; Lechapt-Zalcman, E; Litré, CF; Menei, P; Metellus, P; Peruzzi, P; Rousseaux, P; Théret, E, 2013) |
| "Forty patients with recurrent malignant gliomas had been treated with temozolomide (Temodal)." | 7.71 | [Treatment of recidive malignant gliomas with temozolomide]. ( Afra, D; Sipos, L; Vitanovics, D, 2002) |
| "Temozolomide is a novel second-generation oral alkylating agent with demonstrated efficacy and safety in patients with recurrent glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA)." | 6.70 | A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. ( Friedman, HS; Gilbert, MR; Kuttesch, JF; Olson, JJ; Prados, MD; Reaman, GH; Zaknoen, SL, 2002) |
| "Intracranial anaplastic ependymomas are a very rare entity within the group of adult CNS neoplasms." | 5.37 | Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma. ( Freyschlag, CF; Lohr, F; Schmieder, K; Seiz, M; Thomé, C; Tuettenberg, J, 2011) |
| " Thus, our results show that polymeric nanocapsules are able to increase the intratumoral bioavailability of indomethacin and reduce the growth of implanted gliomas." | 5.35 | Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. ( Battastini, AM; Bernardi, A; Braganhol, E; Edelweiss, MI; Figueiró, F; Guterres, SS; Jäger, E; Pohlmann, AR, 2009) |
| "Disulfiram, a generic alcohol aversion drug, has promising preclinical activity against glioblastoma (GBM)." | 5.22 | A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy. ( Campian, JL; DeWees, TA; Gujar, AD; Huang, J; Kim, AH; Lockhart, AC; Tran, DD; Tsien, CI, 2016) |
| "The purpose of phase 1 was to determine the maximum tolerated dose (MTD) of motexafin gadolinium (MGd) given concurrently with temozolomide (TMZ) and radiation therapy (RT) in patients with newly diagnosed supratentorial glioblastoma multiforme (GBM)." | 5.20 | Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513. ( Ashby, LS; Bovi, JA; Brachman, DG; Curran, WP; Dunbar, EM; Narayan, S; Pugh, SL; Robins, HI; Rockhill, JK; Thomas, TA; Won, M, 2015) |
| " Temozolomide (TMZ) is an alkylating agent that is the first-line chemotherapy for glioblastoma." | 5.17 | Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. ( Colman, H; Conrad, C; Gilbert, MR; Groves, M; Hsu, S; Kang, S; Levin, V; Liu, D; Liu, V; Puduvalli, V; Yuan, Y; Yung, WK; Yust-Katz, S, 2013) |
| "External beam radiation therapy (XRT) with concomitant temozolomide and 6 cycles of adjuvant temozolomide (5/28-day schedule) improves survival in patients with newly diagnosed glioblastoma compared with XRT alone." | 5.14 | A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. ( Chang, E; Colman, H; Conrad, C; de Groot, J; Giglio, P; Gilbert, MR; Gonzalez, J; Groves, MD; Hess, K; Hunter, K; Levin, V; Mahajan, A; Puduvalli, V; Woo, S; Yung, WK, 2010) |
| "Twenty-one patients with recurrent or progressive glioblastoma were enrolled in a prospective phase II trial to determine the safety and efficacy of a 1-week on/1-week off regimen of temozolomide administered at 150 mg/m2 on days 1 to 7 and days 15 to 21 of 28-day treatment cycles." | 5.11 | One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. ( Bamberg, M; Dichgans, J; Küker, WM; Steinbach, JP; Weller, M; Wick, W, 2004) |
| "This Phase II study was designed to determine the median survival time of adults with supratentorial glioblastoma treated with a combination of temozolomide (TMZ) and 13-cis-retinoic acid (cRA) given daily with conventional radiation therapy (XRT)." | 5.11 | A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. ( Butowski, N; Chang, SM; Lamborn, KR; Larson, DA; Malec, M; Page, M; Prados, MD; Rabbitt, J; Sneed, PK; Wara, WM, 2005) |
| "Temozolomide (TMZ) and 13-cis-retinoic acid (cRA) have shown activity in prior single-agent trials of recurrent malignant gliomas (MG)." | 5.10 | Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. ( Chang, S; Cloughesy, T; Fine, H; Fink, K; Greenberg, H; Hess, KR; Jaeckle, KA; Kuhn, J; Mehta, M; Nicholas, MK; Pollack, IF; Prados, M; Schiff, D; Yung, WK, 2003) |
| "A total of 210 patients with supratentorial/nonmetastatic glioblastoma were treated with radiation therapy (RT) plus temozolomide from 2007 to 2016 and had laboratory data on total lymphocyte counts." | 3.88 | Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma. ( Campian, JL; Chang, X; Fergus, S; Hallahan, D; Huang, J; Hui, C; Lin, AJ; Mullen, D; Rao, YJ; Rudra, S; Samson, P; Thotala, D; Tsien, C; Yang, D, 2018) |
| "Despite surgery, radiotherapy (RT) and temozolomide (TMZ), the prognosis of glioblastoma (GBM) patients remains dismal." | 3.81 | Impact of renin-angiotensin system blockade on clinical outcome in glioblastoma. ( Alkhafaji, A; Belin, C; Carpentier, AF; Doridam, J; Januel, E; Levy-Piedbois, C; Marantidou, A; Ursu, R, 2015) |
| "Study the feasibility and effectiveness of a treatment associated surgery, intraoperative chemotherapy (carmustine wafers), and concomitant radiochemotherapy (temozolomide) for the management of newly diagnosed, high-grade gliomas." | 3.79 | Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. ( Colin, P; Debreuve, A; Duntze, J; Eap, C; Emery, E; Guillamo, JS; Jovenin, N; Lechapt-Zalcman, E; Litré, CF; Menei, P; Metellus, P; Peruzzi, P; Rousseaux, P; Théret, E, 2013) |
| "Combined temozolomide (TMZ) and radiation therapy (RT) is often used as initial treatment for anaplastic glioma." | 3.79 | Combined temozolomide and radiation as an initial treatment for anaplastic glioma. ( Chong, DQ; Chua, ET; Lim, KH; Ng, WH; See, SJ; Tan, SH; Tham, CK; Thomas, J, 2013) |
| "The identification and consideration of these factors associated with prolonged functional outcome (preoperative KPS score ≥ 90, seizures, primary glioblastoma, gross-total resection, temozolomide) and decreased functional outcome (older age, coronary artery disease, new postoperative motor deficit) may help guide treatment strategies aimed at improving QOL for patients with glioblastoma." | 3.77 | Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical article. ( Brem, H; Chaichana, KL; Halthore, AN; Olivi, A; Parker, SL; Quinones-Hinojosa, A; Weingart, JD, 2011) |
| "Forty patients with recurrent malignant gliomas had been treated with temozolomide (Temodal)." | 3.71 | [Treatment of recidive malignant gliomas with temozolomide]. ( Afra, D; Sipos, L; Vitanovics, D, 2002) |
| "Temozolomide is a novel second-generation oral alkylating agent with demonstrated efficacy and safety in patients with recurrent glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA)." | 2.70 | A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. ( Friedman, HS; Gilbert, MR; Kuttesch, JF; Olson, JJ; Prados, MD; Reaman, GH; Zaknoen, SL, 2002) |
| " The recommended dosage for TEMO for a phase II study of this combination is 200 mg/m2 per day for 5 days." | 2.70 | Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. ( Affronti, ML; Cokgor, L; Early, M; Edwards, S; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, JH; Stafford-Fox, V; Tourt-Uhlig, S; Zaknoen, S, 2001) |
| "Tremor is the most prevalent movement disorder." | 1.48 | Tremor Secondary to a Thalamic Glioma: A Case Report. ( Elias, WJ; Fadul, CE; Wang, TR, 2018) |
| "Although glioblastoma multiforme is more common in patients older than 65 years, the elderly population is often excluded from clinical studies." | 1.42 | Treatment results and outcome in elderly patients with glioblastoma multiforme--a retrospective single institution analysis. ( Asslaber, M; Bruckmann, L; Hoffermann, M; Kariem Mahdy, A; Payer, F; von Campe, G, 2015) |
| "Intracranial anaplastic ependymomas are a very rare entity within the group of adult CNS neoplasms." | 1.37 | Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma. ( Freyschlag, CF; Lohr, F; Schmieder, K; Seiz, M; Thomé, C; Tuettenberg, J, 2011) |
| " Thus, our results show that polymeric nanocapsules are able to increase the intratumoral bioavailability of indomethacin and reduce the growth of implanted gliomas." | 1.35 | Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. ( Battastini, AM; Bernardi, A; Braganhol, E; Edelweiss, MI; Figueiró, F; Guterres, SS; Jäger, E; Pohlmann, AR, 2009) |
| "Temozolomide (TMZ) has demonstrated activity and acceptable toxicity for the treatment of recurrent high-grade gliomas in prospective phase II studies." | 1.32 | Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium. ( Branle, F; Everaert, E; Joosens, E; Menten, J; Neyns, B; Strauven, T, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (34.15) | 29.6817 |
| 2010's | 23 (56.10) | 24.3611 |
| 2020's | 4 (9.76) | 2.80 |
| Authors | Studies |
|---|---|
| Saito, T | 2 |
| Muragaki, Y | 2 |
| Maruyama, T | 2 |
| Komori, T | 2 |
| Nitta, M | 2 |
| Tsuzuki, S | 1 |
| Fukui, A | 1 |
| Kawamata, T | 2 |
| Drumm, MR | 1 |
| Dixit, KS | 1 |
| Grimm, S | 1 |
| Kumthekar, P | 1 |
| Lukas, RV | 1 |
| Raizer, JJ | 1 |
| Stupp, R | 1 |
| Chheda, MG | 1 |
| Kam, KL | 1 |
| McCord, M | 1 |
| Sachdev, S | 1 |
| Kruser, T | 1 |
| Steffens, A | 1 |
| Javier, R | 1 |
| McCortney, K | 1 |
| Horbinski, C | 1 |
| Jusue-Torres, I | 1 |
| Hulbert, A | 1 |
| Barton, K | 1 |
| Melian, E | 1 |
| Anderson, DE | 1 |
| Quiñones-Hinojosa, A | 2 |
| Prabhu, VC | 1 |
| Zhang, M | 1 |
| Li, R | 1 |
| Pollom, EL | 1 |
| Amini, A | 1 |
| Dandapani, S | 1 |
| Li, G | 1 |
| Nathan, JK | 1 |
| Brezzell, AL | 1 |
| Kim, MM | 1 |
| Leung, D | 1 |
| Wilkinson, DA | 1 |
| Hervey-Jumper, SL | 1 |
| Wang, TR | 1 |
| Fadul, CE | 1 |
| Elias, WJ | 1 |
| Rudra, S | 1 |
| Hui, C | 1 |
| Rao, YJ | 1 |
| Samson, P | 1 |
| Lin, AJ | 1 |
| Chang, X | 1 |
| Tsien, C | 1 |
| Fergus, S | 1 |
| Mullen, D | 1 |
| Yang, D | 1 |
| Thotala, D | 1 |
| Hallahan, D | 1 |
| Campian, JL | 2 |
| Huang, J | 2 |
| Shioyama, T | 1 |
| Yasuda, T | 1 |
| Hosono, J | 1 |
| Okamoto, S | 1 |
| Young, JS | 1 |
| Bernal, G | 1 |
| Polster, SP | 1 |
| Nunez, L | 1 |
| Larsen, GF | 1 |
| Mansour, N | 1 |
| Podell, M | 1 |
| Yamini, B | 1 |
| Schwartz, C | 1 |
| Romagna, A | 1 |
| Machegger, L | 1 |
| Weiss, L | 1 |
| Huemer, F | 1 |
| Fastner, G | 1 |
| Kleindienst, W | 1 |
| Weis, S | 1 |
| Greil, R | 1 |
| Winkler, PA | 1 |
| Li, C | 1 |
| Yan, JL | 1 |
| Torheim, T | 1 |
| McLean, MA | 1 |
| Boonzaier, NR | 1 |
| Zou, J | 1 |
| Huang, Y | 1 |
| Yuan, J | 1 |
| van Dijken, BRJ | 1 |
| Matys, T | 1 |
| Markowetz, F | 1 |
| Price, SJ | 1 |
| Yust-Katz, S | 1 |
| Liu, D | 1 |
| Yuan, Y | 1 |
| Liu, V | 1 |
| Kang, S | 1 |
| Groves, M | 1 |
| Puduvalli, V | 2 |
| Levin, V | 2 |
| Conrad, C | 2 |
| Colman, H | 2 |
| Hsu, S | 1 |
| Yung, WK | 4 |
| Gilbert, MR | 3 |
| Ajlan, A | 1 |
| Recht, L | 1 |
| Hoffermann, M | 1 |
| Bruckmann, L | 1 |
| Kariem Mahdy, A | 1 |
| Asslaber, M | 1 |
| Payer, F | 1 |
| von Campe, G | 1 |
| Xu, DS | 1 |
| Rosenfeld, A | 1 |
| Ponce, FA | 1 |
| Nakaji, P | 1 |
| Bhardwaj, RD | 1 |
| Brachman, DG | 1 |
| Pugh, SL | 1 |
| Ashby, LS | 1 |
| Thomas, TA | 1 |
| Dunbar, EM | 1 |
| Narayan, S | 1 |
| Robins, HI | 1 |
| Bovi, JA | 1 |
| Rockhill, JK | 1 |
| Won, M | 1 |
| Curran, WP | 1 |
| Kazda, T | 1 |
| Pospisil, P | 1 |
| Vrzal, M | 1 |
| Sevela, O | 1 |
| Prochazka, T | 1 |
| Jancalek, R | 1 |
| Slampa, P | 1 |
| Laack, NN | 1 |
| Januel, E | 1 |
| Ursu, R | 1 |
| Alkhafaji, A | 1 |
| Marantidou, A | 1 |
| Doridam, J | 1 |
| Belin, C | 1 |
| Levy-Piedbois, C | 1 |
| Carpentier, AF | 1 |
| Gujar, AD | 1 |
| Tran, DD | 1 |
| Lockhart, AC | 1 |
| DeWees, TA | 1 |
| Tsien, CI | 1 |
| Kim, AH | 1 |
| Bernardi, A | 1 |
| Braganhol, E | 1 |
| Jäger, E | 1 |
| Figueiró, F | 1 |
| Edelweiss, MI | 1 |
| Pohlmann, AR | 1 |
| Guterres, SS | 1 |
| Battastini, AM | 1 |
| Chamberlain, MC | 1 |
| Johnston, SK | 1 |
| Chaichana, KL | 1 |
| Halthore, AN | 1 |
| Parker, SL | 1 |
| Olivi, A | 1 |
| Weingart, JD | 1 |
| Brem, H | 1 |
| Gonzalez, J | 1 |
| Hunter, K | 1 |
| Hess, K | 1 |
| Giglio, P | 1 |
| Chang, E | 1 |
| Groves, MD | 1 |
| Woo, S | 1 |
| Mahajan, A | 1 |
| de Groot, J | 1 |
| Lawrence, YR | 1 |
| Wang, M | 1 |
| Dicker, AP | 1 |
| Andrews, D | 1 |
| Curran, WJ | 1 |
| Michalski, JM | 1 |
| Souhami, L | 1 |
| Mehta, M | 2 |
| Freyschlag, CF | 1 |
| Tuettenberg, J | 1 |
| Lohr, F | 1 |
| Thomé, C | 1 |
| Schmieder, K | 1 |
| Seiz, M | 1 |
| Desjardins, A | 1 |
| Sampson, JH | 2 |
| Wheeler, H | 1 |
| Black, J | 1 |
| Webb, S | 1 |
| Shen, H | 1 |
| Duntze, J | 1 |
| Litré, CF | 1 |
| Eap, C | 1 |
| Théret, E | 1 |
| Debreuve, A | 1 |
| Jovenin, N | 1 |
| Lechapt-Zalcman, E | 1 |
| Metellus, P | 1 |
| Colin, P | 2 |
| Guillamo, JS | 1 |
| Emery, E | 1 |
| Menei, P | 1 |
| Rousseaux, P | 1 |
| Peruzzi, P | 1 |
| Tham, CK | 1 |
| See, SJ | 1 |
| Tan, SH | 1 |
| Lim, KH | 1 |
| Ng, WH | 1 |
| Thomas, J | 1 |
| Chong, DQ | 1 |
| Chua, ET | 1 |
| Friedman, HS | 2 |
| Kuttesch, JF | 1 |
| Prados, MD | 4 |
| Olson, JJ | 1 |
| Reaman, GH | 1 |
| Zaknoen, SL | 1 |
| Jaeckle, KA | 1 |
| Hess, KR | 1 |
| Greenberg, H | 1 |
| Fine, H | 1 |
| Schiff, D | 1 |
| Pollack, IF | 1 |
| Kuhn, J | 1 |
| Fink, K | 1 |
| Cloughesy, T | 1 |
| Nicholas, MK | 1 |
| Chang, S | 1 |
| Prados, M | 1 |
| Keles, GE | 1 |
| Lamborn, KR | 3 |
| Chang, SM | 2 |
| Berger, MS | 2 |
| Wick, W | 1 |
| Steinbach, JP | 1 |
| Küker, WM | 1 |
| Dichgans, J | 1 |
| Bamberg, M | 1 |
| Weller, M | 1 |
| Everaert, E | 1 |
| Neyns, B | 1 |
| Joosens, E | 1 |
| Strauven, T | 1 |
| Branle, F | 1 |
| Menten, J | 1 |
| Butowski, N | 1 |
| Larson, DA | 1 |
| Sneed, PK | 1 |
| Wara, WM | 1 |
| Malec, M | 2 |
| Rabbitt, J | 1 |
| Page, M | 1 |
| Haas-Kogan, DA | 1 |
| Tihan, T | 1 |
| Eberhard, DA | 1 |
| Jelluma, N | 1 |
| Arvold, ND | 1 |
| Baumber, R | 1 |
| Kapadia, A | 1 |
| Stokoe, D | 1 |
| Ducray, F | 1 |
| Cartalat-Carel, S | 1 |
| Pelissou-Guyotat, I | 1 |
| Mahla, K | 1 |
| Audra, P | 1 |
| Gaucherand, P | 1 |
| Honnorat, J | 1 |
| Trouillas, P | 1 |
| Terheggen, F | 1 |
| Troost, D | 1 |
| Majoie, CB | 1 |
| Leenstra, S | 1 |
| Richel, DJ | 1 |
| Terasaki, M | 1 |
| Ogo, E | 1 |
| Fukushima, S | 1 |
| Sakata, K | 1 |
| Miyagi, N | 1 |
| Abe, T | 1 |
| Shigemori, M | 1 |
| Gururangan, S | 1 |
| Cokgor, L | 1 |
| Rich, JN | 1 |
| Edwards, S | 1 |
| Affronti, ML | 1 |
| Quinn, JA | 1 |
| Herndon, JE | 1 |
| Provenzale, JM | 1 |
| McLendon, RE | 1 |
| Tourt-Uhlig, S | 1 |
| Stafford-Fox, V | 1 |
| Zaknoen, S | 1 |
| Early, M | 1 |
| Friedman, AH | 1 |
| Sipos, L | 1 |
| Vitanovics, D | 1 |
| Afra, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A PHASE I/II TRIAL OF TEMOZOLOMIDE, MOTEXAFIN GADOLINIUM, AND 60 GY FRACTIONATED RADIATION FOR NEWLY DIAGNOSED SUPRATENTORIAL GLIOBLASTOMA MULTIFORME[NCT00305864] | Phase 1/Phase 2 | 118 participants (Actual) | Interventional | 2006-02-09 | Completed | ||
| A Prospective Phase II Study in Patients With Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era[NCT03138642] | Phase 2 | 30 participants (Anticipated) | Interventional | 2010-07-01 | Recruiting | ||
| Evaluation of Topical Application of 5% Imiquimod, 0.05% Imiquimod and 0.05% Nanoencapsulated Imiquimod Gel in the Treatment of Actinic Cheilitis: a Randomized Controlled Trial[NCT04219358] | Phase 1 | 49 participants (Actual) | Interventional | 2019-03-23 | Terminated (stopped due to Study terminated because of COVID19 pandemics.) | ||
| A Randomized, Factorial-Design, Phase II Trial of Temozolomide Alone and in Combination With Possible Permutations of Thalidomide, Isotretinoin and/or Celecoxib as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme[NCT00112502] | Phase 2 | 178 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Patients were to be followed for a minimum of 90 days from the start of radiation therapy (RT) and carefully evaluated with respect to treatment morbidity. A dose limiting toxicity (DLT) was defined as a grade 4 neurologic adverse event (AE) considered to be related to treatment occurring within 21 days of the conclusion of RT. For each dose level, up to seven patients were to be accrued to assure that there would be six eligible for treatment adverse event evaluation. A dose level of MGd was considered acceptable if no more than 1 patient of the 6 experience a DLT. If the current level was considered acceptable, then dose escalation occurred. Otherwise, the preceding dose level would be declared the maximum tolerated dose (MTD). The MTD would be used for the Phase II arm.~Rating scale: 0 = not the MTD, 1 = MTD" (NCT00305864)
Timeframe: From start of radiation therapy to 90 days,
| Intervention | units on a scale (Number) |
|---|---|
| Phase I: MGd 3 mg/kg | 0 |
| Phase I: MGd 4 mg/kg | 0 |
| Phase I: 5 mg/kg | 1 |
Survival time was defined as the time from baseline to date of death from any cause. Patients last known to be alive are censored at date of last contact. (NCT00305864)
Timeframe: From randomization to date of death or last follow-up. Analysis occurs after all patients have been potentially followed for at least 18 months. Patients were followed up to 54.3 months
| Intervention | Months (Median) |
|---|---|
| All MGd 5mg/kg Patients (Phase I and II Arms Combined) | 15.6 |
Progression will be defined as a > 25% increase in tumor area. Progression-free survival time was defined as the time from baseline to date of death from any cause. Patients last known to be alive are censored at date of last contact. (NCT00305864)
Timeframe: From randomization to date of progression, death, or last follow-up. Analysis occurs after all patients have been potentially followed for at least 18 months. Patients were followed up to 54.3 months.
| Intervention | months (Median) |
|---|---|
| All MGd 5mg/kg Patients (Phase I and II Arms Combined) | 7.6 |
Celecoxib versus not Celecoxib analysis: We compared the median OS outcome of participants in arms III, V, VI and VIII, versus participants in arms I, II, IV and VII. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Celecoxib: Arm III, Arm V, Arm VI and Arm VIII | 20.2 |
| No Celecoxib: Arm I, Arm II, Arm IV and Arm VII | 17.1 |
Doublet (2 agents) versus Triplet (3 agents) therapy analysis: We compared the median OS outcome of participants in arms II, III, IV, versus participants in arms V, VI and VII. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Doublet (2 Agents): Arm II, Arm III and Arm IV | 17.0 |
| Triplet (3 Agents): Arm V, Arm VI and Arm VII | 20.1 |
Isotretinoin versus not Isotretinoin analysis: We compared the median OS outcome of participants in arms IV, V, VII and VIII, versus participants in arms I, II, III and VI. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Isotretinoin: Arm IV, Arm V, Arm VII and ARM VIII | 17.1 |
| No Isotretinoin: Arm I, Arm II, Arm III and ARM VI | 19.9 |
Thalidomide versus not Thalidomide analysis: We compared the median OS outcome of participants in arms II, VI, VII and VIII, versus participants in arms I, III, IV and V. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Thalidomide: Arm II, Arm VI, Arm VII and Arm VIII | 18.3 |
| No Thalidomide: Arm I, Arm III, Arm IV and Arm V | 17.4 |
Celecoxib versus not Celecoxib analysis: We compared the median PFS outcome of participants in arms III, V, VI and VIII, versus participants in arms I, II, IV and VII. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Celecoxib: Arm III, Arm V, Arm VI and Arm VIII | 8.3 |
| No Celecoxib: Arm I, Arm II, Arm IV and Arm VII | 7.4 |
Doublet (2 agents) versus Triplet (3 agents) therapy analysis: We compared the median PFS outcome of participants in arms II, III, IV, versus participants in arms V, VI and VII. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Doublet (2 Agents): Arm II, Arm III and Arm IV | 8.3 |
| Triplet (3 Agents): Arm V, Arm VI and Arm VII | 8.2 |
Isotretinoin versus not Isotretinoin analysis: We compared the median PFS outcome of participants in arms IV, V, VII and VIII, versus participants in arms I, II, III and VI. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Isotretinoin: Arm IV, Arm V, Arm VII and Arm VIII | 6.6 |
| No Isotretinoin: Arm I, Arm II, Arm III and Arm VI | 9.1 |
Thalidomide versus not Thalidomide analysis: Comparison of median PFS outcome of participants in arms II, VI, VII and VIII, versus participants in arms I, III, IV and V. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up, up to one year (12 study cycles).
| Intervention | months (Median) |
|---|---|
| Thalidomide: Arm II, Arm VI, Arm VII and Arm VIII | 7.6 |
| No Thalidomide: Arm I, Arm III, Arm IV and Arm V | 8.7 |
Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Arm I: TMZ | 10.5 |
| Arm II: TMZ + Thalidomide | 7.7 |
| Arm III: TMZ + Celecoxib | 13.4 |
| Arm IV: TMZ + Isotretinoin | 6.5 |
| Arm V: TMZ + Isotretinoin + Celecoxib | 11.6 |
| Arm VI: TMZ + Thalidomide + Celecoxib | 7.9 |
| Arm VII: TMZ + Thalidomide + Isotretinoin | 6.2 |
| Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib | 5.8 |
Overall Survival (OS) was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.
| Intervention | months (Median) |
|---|---|
| Arm I: TMZ | 21.2 |
| Arm II: TMZ + Thalidomide | 17.4 |
| Arm III: TMZ + Celecoxib | 18.1 |
| Arm IV: TMZ + Isotretinoin | 11.7 |
| Arm V: TMZ + Isotretinoin + Celecoxib | 23.1 |
| Arm VI: TMZ + Thalidomide + Celecoxib | 20.2 |
| Arm VII: TMZ + Thalidomide + Isotretinoin | 17.9 |
| Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib | 18.5 |
1 review available for temozolomide and Benign Supratentorial Neoplasms
| Article | Year |
|---|---|
Supratentorial low-grade diffuse astrocytoma: medical management.
Topics: Antineoplastic Agents; Astrocytoma; Dacarbazine; Disease Progression; Humans; Neoplasm Grading; Nitr | 2014 |
12 trials available for temozolomide and Benign Supratentorial Neoplasms
| Article | Year |
|---|---|
Convection-Enhanced Delivery of Polymeric Nanoparticles Encapsulating Chemotherapy in Canines with Spontaneous Supratentorial Tumors.
Topics: Animals; Antineoplastic Agents; Brain; Convection; Dacarbazine; Dog Diseases; Dogs; Drug Delivery Sy | 2018 |
Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Fem | 2013 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Dacarbazine; Disulfiram | 2016 |
A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Celecoxib; Chemotherapy, Adjuvant; Combined Modality | 2010 |
A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; Fe | 2002 |
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazin | 2003 |
Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Human | 2004 |
One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Prog | 2004 |
A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Comb | 2005 |
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve | 2005 |
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Cohort Studies | 2001 |
28 other studies available for temozolomide and Benign Supratentorial Neoplasms
| Article | Year |
|---|---|
Influence of wide opening of the lateral ventricle on survival for supratentorial glioblastoma patients with radiotherapy and concomitant temozolomide-based chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Female; Glioblastoma; | 2020 |
Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas.
Topics: Aged; Brain Neoplasms; Brain Stem; Glioblastoma; Humans; Supratentorial Neoplasms; Temozolomide | 2020 |
Survival benefit of concomitant chemoradiation in adult supratentorial primary glioblastoma. A propensity score weighted population-based analysis.
Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Kaplan-Meier Estimate; Propensity Score; Supratentoria | 2022 |
Treatment patterns and outcomes for cerebellar glioblastoma in the concomitant chemoradiation era: A National Cancer database study.
Topics: Adult; Aged; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality | 2020 |
Early initiation of chemoradiation following index craniotomy is associated with decreased survival in high-grade glioma.
Topics: Age Factors; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Craniotomy; Dacarbazine; Female; | 2017 |
Tremor Secondary to a Thalamic Glioma: A Case Report.
Topics: Antineoplastic Agents; Astrocytoma; Biopsy; Chemotherapy, Adjuvant; Combined Modality Therapy; Crani | 2018 |
Effect of Radiation Treatment Volume Reduction on Lymphopenia in Patients Receiving Chemoradiotherapy for Glioblastoma.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bevacizumab; Carmu | 2018 |
Malignancy Index Using Intraoperative Flow Cytometry is a Valuable Prognostic Factor for Glioblastoma Treated With Radiotherapy and Concomitant Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Drug Resistance, Neoplasm; Female | 2019 |
Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunol | 2018 |
Low perfusion compartments in glioblastoma quantified by advanced magnetic resonance imaging and correlated with patient survival.
Topics: Adult; Aged; Chemoradiotherapy; Cohort Studies; Diffusion Magnetic Resonance Imaging; Female; Gliobl | 2019 |
Treatment results and outcome in elderly patients with glioblastoma multiforme--a retrospective single institution analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Combined Modality Therapy; | 2015 |
Cerebral peduncle tumor ablated by novel 3-mm laser tip.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Camptothecin; Cerebral Ped | 2015 |
Volumetric modulated arc therapy for hippocampal-sparing radiotherapy in transformed low-grade glioma: A treatment planning case report.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Damage, Chronic; Cell Dedifferentiation; Combi | 2015 |
Impact of renin-angiotensin system blockade on clinical outcome in glioblastoma.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antineoplas | 2015 |
Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Body Weight; Cell Division; Cell | 2009 |
Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Carboplatin; Cisplatin; Dacarbazine; Disease-Free Survival | 2009 |
Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical article.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modal | 2011 |
Early toxicity predicts long-term survival in high-grade glioma.
Topics: Acute Disease; Adult; Aged; Analysis of Variance; Antineoplastic Agents; Chemotherapy, Adjuvant; Dac | 2011 |
Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Ependymoma; Female; | 2011 |
Avastin: more questions than answers. . .
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2012 |
Dehiscence of corticosteroid-induced abdominal striae in a 14-year-old boy treated with bevacizumab for recurrent glioblastoma.
Topics: Adolescent; Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkyl | 2012 |
Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherapy, Adjuvant; Dacarbazine | 2013 |
Combined temozolomide and radiation as an initial treatment for anaplastic glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease Progression; Diseas | 2013 |
Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Belgium; Brain Neoplasms; Dacarba | 2004 |
[Management of malignant gliomas diagnosed during pregnancy].
Topics: Abortion, Therapeutic; Adrenal Cortex Hormones; Adult; Algorithms; Anesthesia, General; Antineoplast | 2006 |
Local recurrence and distant metastasis of supratentorial primitive neuro-ectodermal tumor in an adult patient successfully treated with intensive induction chemotherapy and maintenance temozolomide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Cyclophosphamide; Daca | 2007 |
Impact of combination therapy with repeat surgery and temozolomide for recurrent or progressive glioblastoma multiforme: a prospective trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Cohort Studies; | 2007 |
[Treatment of recidive malignant gliomas with temozolomide].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioma; Humans; Male; Middle Ag | 2002 |